Triple

T22690342
Position Surface form Disambiguated ID Type / Status
Subject IL-17A E561033 entity
Predicate producedByCellType P95984 FINISHED
Object CD8-positive T cell NE NERFINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: CD8-positive T cell | Statement: [IL-17A, producedByCellType, CD8-positive T cell]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: CD8-positive T cell
Context triple: [IL-17A, producedByCellType, CD8-positive T cell]
  • A. CD8+ T cells chosen
    CD8+ T cells are cytotoxic lymphocytes of the adaptive immune system that identify and kill infected or malignant cells by recognizing antigenic peptides presented on MHC class I molecules.
  • B. CD4+ T cells
    CD4+ T cells are a subset of immune cells that coordinate and regulate the body’s adaptive immune response, playing a central role in defending against infections.
  • C. T lymphocytes
    T lymphocytes are white blood cells central to the adaptive immune system, responsible for recognizing specific antigens and orchestrating targeted immune responses.
  • D. B lymphocytes
    B lymphocytes are a type of white blood cell central to the adaptive immune system, responsible for producing antibodies and mediating humoral immunity.
  • E. CD19
    CD19 is a B-cell surface protein widely used as a key immunotherapy target in treatments for B-cell malignancies such as certain leukemias and lymphomas.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e2454d71b48190a1f80af9f82b6fcf completed April 17, 2026, 2:35 p.m.
NER Named-entity recognition batch_69f1789a1fd08190bce5fa0babe695d3 completed April 29, 2026, 3:18 a.m.
Created at: April 17, 2026, 3:13 p.m.